Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it ...

GLP-1 drugs were also linked with better graft and patient survival in kidney transplant recipients with type 2 diabetes.

Reducing that frequency could be a competitive advantage against similarly-dosed rivals like Eli Lilly's tirzepatide-based Mounjaro and Zepbound, help patients comply with treatment, and ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...